Clinically, using estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) as markers, breast cancer patients are mainly classified into ER+, HER2 + and triple-negative breast cancer (TNBC) subtypes. This evidence concerns the gene ERBB2 and breast cancer.